Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Clin Obstet Gynecol. 2010 Dec;53(4):740-52. doi: 10.1097/GRF.0b013e3181f96cb1.

Use of hormonal protection for chemotherapy-induced gonadotoxicity.

Author information

  • 1Department of Obstetrics and Gynecology, University of Kansas School of Medicine, Kansas City, KS, USA. skim2@kumc.edu

Abstract

It is still controversial that GnRH agonist (GnRHa) protects ovarian function from chemotherapy-induced gonadotoxicity. Indeed, the results of many studies related to this issue are neither consistent nor convincing because of the weak study design and the inadequate sample size. We identified 11 prospective controlled studies (8 nonrandomized and 3 randomized) for the systemic review and meta-analysis. The meta-analysis showed that GnRHa cotreatment during chemotherapy can protect ovarian function. However, it is worthy to note that the result of this meta-analysis is influenced by nonrandomized studies. The protective effect of GnRHa will remain elusive until the currently ongoing large, prospective, randomized studies are completed. In addition, tamoxifen, a selective estrogen receptor modulator, may have the protective effect against loss of follicles and ovarian function, which was caused by chemotherapy.

PMID:
21048441
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Lippincott Williams & Wilkins
    Loading ...
    Write to the Help Desk